Theravance Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 6, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	877	956	466	541	732	823
Market Cap Growth	58.15%	105.25%	-13.88%	-26.14%	-11.02%	-28.05%
Enterprise Value	522.77	682.85	426.99	487.28	456.52	1,319
Last Close Price	16.92	18.71	9.41	11.24	11.22	11.05
PE Ratio	7.65	9.08	-	-	0.95	-
Forward PE	7.62	25.83	29.96	29.96	29.96	-
PS Ratio	7.99	8.89	7.23	9.41	14.25	14.87
PB Ratio	3.00	3.22	2.65	2.54	1.66	-2.43
P/TBV Ratio	3.02	3.25	2.62	2.92	1.87	-
P/FCF Ratio	3.26	4.01	-	-	-	-
P/OCF Ratio	3.26	4.01	-	-	-	-
EV/Sales Ratio	4.76	6.35	6.63	8.49	8.89	23.84
EV/EBITDA Ratio	74.18	334.89	-	-	-	-
EV/FCF Ratio	1.95	2.86	-	-	-	-
Debt / Equity Ratio	0.10	0.11	0.22	0.21	0.10	-1.93
Debt / EBITDA Ratio	5.75	20.94	-	-	-	-
Debt / FCF Ratio	0.15	0.18	-	-	-	-
Net Debt / Equity Ratio	-1.22	-0.92	-0.22	-0.25	-0.62	-1.46
Net Debt / EBITDA Ratio	-50.26	-133.72	0.94	1.07	3.27	-1.99
Net Debt / FCF Ratio	-1.32	-1.14	3.25	1.81	1.47	-2.35
Asset Turnover	0.23	0.26	0.17	0.12	0.10	0.13
Quick Ratio	12.91	10.73	4.89	4.84	11.99	3.20
Current Ratio	13.14	10.93	5.02	5.39	12.31	4.26
Return on Equity (ROE)	0.53%	54.73%	-22.96%	-15.05%	-179.83%	82.53%
Return on Assets (ROA)	-0.07%	-0.86%	-12.76%	-11.33%	-18.72%	-61.06%
Return on Invested Capital (ROIC)	-	-4.47%	-31.64%	-34.36%	-38.10%	-77.87%
Return on Capital Employed (ROCE)	0.30%	-0.94%	-13.82%	-11.97%	-20.55%	-77.91%
Earnings Yield	13.06%	11.01%	-	-	105.61%	-
FCF Yield	30.65%	24.96%	-	-	-	-
Buyback Yield / Dilution	-5.48%	-5.45%	11.67%	24.85%	-5.95%	-11.41%
Total Shareholder Return	-5.48%	-5.45%	11.67%	24.85%	-5.95%	-11.41%

SEC Filings: 10-K · 10-Q